Pediatric cardiomyopathies: Causes, epidemiology, clinical course, preventive strategies and therapies

Future Cardiology

Volumn 9, Issue 6, 2013, Pages 817-848

  Lipshultz, Steven E ^a,b   Cochran, Thomas R ^a   Briston, David A ^a   Brown, Stefanie R ^a   Sambatakos, Peter J ^a   Miller, Tracie L ^a,b   Carrillo, Adriana A ^a   Corcia, Liat ^a   Sanchez, Janine E ^a   Diamond, Melissa B ^a   Freundlich, Michael ^a   Harake, Danielle ^a   Gayle, Tamara ^a   Harmon, William G ^a   Rusconi, Paolo G ^a   Sandhu, Satinder K ^a   Wilkinson, James D ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

cardiomyopathy; heart failure; pediatric; risk factors; transplantation; treatment

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA CRYSTALLIN; ALPHA TOCOPHEROL; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; DESMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DIURETIC AGENT; FIBROBLAST GROWTH FACTOR 23; REACTIVE OXYGEN METABOLITE; SELENIUM; TAURINE; THYROXINE; TRACE ELEMENT; TROPONIN I; VERAPAMIL; VITAMIN D; ZINC;

ADULTHOOD; ALSTROM SYNDROME; ANTICOAGULANT THERAPY; ARTIFICIAL VENTILATION; ASSISTED CIRCULATION; CANCER RADIOTHERAPY; CANCER SURVIVOR; CARDIAC PATIENT; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CHILDHOOD CANCER; CHILDHOOD DISEASE; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CONGESTIVE CARDIOMYOPATHY; DEFIBRILLATOR; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; DIET SUPPLEMENTATION; DISEASE COURSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FOLLOW UP; GRAFT SURVIVAL; HEART CATHETERIZATION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE BIOPSY; HEART PALPITATION; HEART RIGHT VENTRICLE DYSPLASIA; HEART SCINTISCANNING; HEART TRANSPLANTATION; HEART VENTRICLE FILLING; HEART VENTRICLE HYPERTROPHY; HEMOCHROMATOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTHYROIDISM; HYPERTROPHIC CARDIOMYOPATHY; IMMUNOSUPPRESSIVE TREATMENT; INHERITANCE; KEARNS SAYRE SYNDROME; LIFE EXPECTANCY; LONG TERM CARE; MACRONUTRIENT; NOONAN SYNDROME; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; PHENOTYPE; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; RESTRICTIVE CARDIOMYOPATHY; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SUDDEN CARDIAC DEATH; SYSTOLIC DYSFUNCTION; TAKOTSUBO CARDIOMYOPATHY; THORAX RADIOGRAPHY; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

CARDIOMYOPATHIES; CHILD; CHRONIC DISEASE; DISEASE MANAGEMENT; DISEASE PROGRESSION; HUMANS; INCIDENCE; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PROGNOSIS; RISK FACTORS; UNITED STATES;

EID: 84887227795     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.13.66     Document Type: Review

References (225)

1. Wilkinson JD, Sleeper LA, Alvarez JA, Bublik N, Lipshultz SE; for the Pediatric Cardiomyopathy Study Group. The pediatric cardiomyopathy registry: 1995-2007. Prog. Pediatr. Cardiol. 25(1), 31-36 (2008).
2. Lipshultz SE, Sleeper LA, Towbin JA et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N. Engl. J. Med. 348(17), 1647-1655 (2003). Found that the incidence of cardiomyopathy was significantly higher in children younger than 1 year old. The estimated incidence of pediatric cardiomyopathy was determined to be 1.13 cases per 100,000 children. Incidence varied according to sex, region and racial origin.
3. Bublik N, Alvarez JA, Lipshultz SE. Pediatric cardiomyopathy as a chronic disease: A perspective on comprehensive care programs. Prog. Pediatr. Cardiol. 25(1), 103-111 (2008).
4. Alvarez JA, Wilkinson JD, Lipshultz SE; for the Pediatric Cardiomyopathy Registry Study Group. Outcome predictors for pediatric dilated cardiomyopathy: A systematic review. Prog. Pediatr. Cardiol. 23(1), 25-32 (2007).
5. Towbin JA, Lowe AM, Colan SD et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 296(15), 1867-1876 (2006).
6. Towbin JA, Sleeper LA, Lowe AM et al. Etiology, incidence, and outcome of dilated cardiomyopathy in children: The pediatric cardiomyopathy registry experience. JAMA 296(15), 1867-1876 (2006).
7. Fisher SD, Easley KA, Orav EJ et al. Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: The prospective P2C2 HIV multicenter study. Am. Heart J. 150(3), 439-447 (2005).
8. Lipshultz SE. Dilated cardiomyopathy in HIV-infected patients. N. Engl. J. Med. 339(16), 1153-1155 (1998).
9. Lipshultz SE, Colan SD, Gelber RD et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 324, 808-815 (1991).
10. Lipshultz SE, Lipsitz SR, Sallan SE et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J. Clin. Oncol. 23, 2629-2636 (2005).
11. Singh TP, Sleeper LA, Lipshultz SE et al. Association of left ventricular dilation at listing for heart transplant with post-listing and early post-transplant mortality in children with dilated cardiomyopathy. Circ. Heart Fail. 2(6), 591-598 (2009).
12. Kantor PF, Orav EJ, Wilkinson JD et al. Progressive left ventricular changes predict the likelihood of survival in pediatric dilated cardiomyopathy: Findings from the pediatric cardiomyopathy registry. Presented at: ACC Scientific Sessions. Chicago, IL, USA, 24-27 March 2012.
13. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling - concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J. Am. Coll. Cardiol. 35(3), 569-582 (2000).
14. Rusconi PG, Ludwig DA, Ratnasamy C et al. Serial measurements of serum NT-proBNP as markers of left ventricular systolic function and remodeling in children with heart failure. Am. Heart J. 160(4), 776-783 (2010).
15. Harmon WG, Sleeper LA, Cuniberti L et al. Treating children with idiopathic dilated cardiomyopathy (from the Pediatric Cardiomyopathy Registry). Am. J. Cardiol. 104(2), 281-286 (2009).
16. Harmon WG, Sleeper LA, Cuniberti L et al. Practice patterns in treating children with dilated cardiomyopathy: Findings from the North American Pediatric Cardiomyopathy Registry. Am. J. Cardiol. 104(2), 281-286 (2009).
17. Alvarez JA, Orav EJ, Wilkinson JD et al. Competing risks for death and cardiac transplantation in children with dilated cardiomyopathy: Results from the Pediatric Cardiomyopathy Registry. Circulation 124(7), 814-823 (2011).
18. Connuck DM, Sleeper LA, Colan SD et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: A comparative study from the Pediatric Cardiomyopathy Registry. Am. Heart J. 155(6), 998-1005 (2008).
19. Wilkinson JD, Landy DC, Colan SD et al. The Pediatric Cardiomyopathy Registry and heart failure: Key results from the first 15 years. Heart Fail. Clin. 6(4), 401-413 (2010).
20. Miyamoto SD, Stauffer BL, Nakano S et al. Beta-adrenergic adaptation in paediatric idiopathic dilated cardiomyopathy. Eur. Heart J. doi:10.1093/ eurheartj/ehs229 (2012) (Epub ahead of print).
21. Lipshultz SE, Wilkinson JD. Beta-adrenergic adaptation in idiopathic dilated cardiomyopathy presenting in pediatric patients contrasted with adult presentations. Eur. Heart J. doi:10.1093/eurheartj/ehs402 (2012) (Epub ahead of print).
22. Pahl E, Sleeper LA, Canter CE et al. Incidence of and risk factors for sudden cardiac death in children with dilated cardiomyopathy: A report from the Pediatric Cardiomyopathy Registry. J. Am. Coll. Cardiol. 59(6), 607-615 (2012).
23. Larsen RL, Canter CE, Naftel DC et al. The impact of heart failure severity at time of listing for cardiac transplantation on survival in pediatric cardiomyopathy. J. Heart Lung Transplant. 30(7), 755-760 (2011).
24. Tsirka AE, Trinkaus K, Chen SC et al. Improved outcomes of pediatric dilated cardiomyopathy with utilization of cardiac transplantation. J. Am. Coll. Cardiol. 44(2), 391-397 (2004).
25. Foerster SR, Canter CE, Cinar A et al. Ventricular remodeling and survival are more favorable for myocarditis than for idiopathic dilated cardiomyopathy in childhood: An outcomes study from the Pediatric Cardiomyopathy Registry. Circ. Heart Fail. 3(6), 689-697 (2010).
26. Pietra BA, Kantor PF, Bartlett HL et al. Early predictors of survival to and after heart transplantation in children with dilated cardiomyopathy. Circulation 126(9), 1079-1086 (2012).
27. Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 124(24), 2761-2796 (2011).
28. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: Morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J. Am. Coll. Cardiol. 26(7), 1699-1708 (1995).
29. Maskatia SA. Hypertrophic cardiomyopathy: Infants, children, and adolescents. Congenit. Heart Dis. 7(1), 84-92 (2012).
30. Decker JA, Rossano JW, Smith EO et al. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children. J. Am. Coll. Cardiol. 54(3), 250-254 (2009).
31. Colan SD, Lipshultz SE, Lowe AM et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: Findings from the Pediatric Cardiomyopathy Registry. Circulation 115(6), 773-781 (2007).
32. Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: Clinical perspectives. J. Am. Coll. Cardiol. 60(8), 705-715 (2012).
33. Botvinick EH, Dae MW, Krishnan R, Ewing S. Hypertrophic cardiomyopathy in the young: Another form of ischemic cardiomyopathy J. Am. Coll. Cardiol. 22(3), 805-807 (1993).
34. Garson A Jr. Sudden death in the young. Hosp. Pract. (Off. Ed.) 26(6), 51-60 (1991).
35. Gow RM. Sudden cardiac death in the young. Can. J. Cardiol. 12(11), 1157-1160 (1996).
36. Liberthson RR. Sudden death from cardiac causes in children and young adults. N. Engl. J. Med. 334(16), 1039-1044 (1996).
37. Driscoll DJ, Edwards WD. Sudden unexpected death in children and adolescents. J. Am. Coll. Cardiol. 5(Suppl. 6), B118-B121 (1985).
38. Lipshultz SE, Orav EJ, WIkinson JD et al. A risk stratification analysis of predictors of death or transplant in children with hypertrophic cardiomyopathy. Circulation 118, S964, Abstract 4956 (2008).
39. Cox GF, Sleeper LA, Lowe AM et al. Factors associated with establishing a causal diagnosis for children with cardiomyopathy. Pediatrics 118(4), 1519-1531 (2006).
40. Ho CY. New paradigms in hypertrophic cardiomyopathy: Insights from genetics. Prog. Pediatr. Cardiol. 31(2), 93-98 (2011).
41. Wilkinson JD, Lowe AM, Salbert BA et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: A study from the Pediatric Cardiomyopathy Registry. Am. Heart J. 164(3), 442-448 (2012).
42. Webber SA, Lipshultz SE, Sleeper La et al. Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: A report from the Pediatric Cardiomyopathy Registry. Circulation 126(10), 1237-1244 (2012).
43. Maron BJ, Douglas PS, Graham TP, Nishimura RA, Thompson PD. Task Force 1: Preparticipation screening and diagnosis of cardiovascular disease in athletes. J. Am. Coll. Cardiol. 45(8), 1322-1326 (2005).
44. Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: Improved survival following high-dose beta-adrenoceptor antagonist treatment. J. Am. Coll. Cardiol. 34(6), 1813-1822 (1999).
45. Ostman-Smith I. Hypertrophic cardiomyopathy in childhood and adolescence - strategies to prevent sudden death. Fund. Am. Clin. Pharmacol. 24(5), 637-652 (2010).
46. Theodoro DA, Danielson GK, Feldt RH, Anderson BJ. Hypertrophic obstructive cardiomyopathy in pediatric patients: Results of surgical treatment. J. Thorac. Cardiovasc. Surg. 112(6), 1589-1597; discussion 1597-1589 (1996).
47. Moss AJ, Hall WJ, Cannom DS et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N. Engl. J. Med. 335(26), 1933-1940 (1996).
48. Lenarczyk R, Kowalski O, Kukulski T, Kowalczyk J, Kalarus Z. Resynchronization or dyssynchronization - successful treatment with biventricular stimulation of a child with obstructive hypertrophic cardiomyopathy without dyssynchrony. J. Cardiovasc. Electrophysiol. 18(5), 542-544 (2007).
49. Spirito P, Autore C, Rapezzi C et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 119(13), 1703-1710 (2009).
50. Dadlani GH, Harmon WG, Perez-Colon E, Sokoloski MC, Wilmot I, Lipshultz SE. Diagnosis and screening of hypertrophic cardiomyopathy in children. Prog. Pediatr. Cardiol. 31(1), 21-27 (2011).
51. Rodday AM, Triedman JK, Alexander ME et al. Electrocardiogram screening for disorders that cause sudden cardiac death in asymptomatic children: A meta-analysis. Pediatrics 129(4), e999-e1010 (2012).
52. Maron BJ, Zipes DP. 36th Bethesda Conference: Eligibility recommendataions for competitive atheletes with cardiovascular abnormalities. J. Am. Coll. Cardiol. 45(8), 1313-1375 (2005).
53. Maron BJ, Towbin JA, Thiene G et al. Contemporary definitions and classification of the cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113(14), 1807-1816 (2006).
54. Chen SC, Balfour IC, Jureidini S. Clinical spectrum of restrictive cardiomyopathy in children. J. Heart Lung Transplant. 20(1), 90-92 (2001).
55. Keren A, Popp RL. Assignment of patients into the classification of cardiomyopathies. Circulation 86(5), 1622-1633 (1992).
56. Russo LM, Webber SA. Idiopathic restrictive cardiomyopathy in children. Heart 91(9), 1199-1202 (2005).
57. Denfield SW, Rosenthal G, Gajarski RJ et al. Restrictive cardiomyopathies in childhood. Etiologies and natural history. Tex. Heart Inst. J. 24(1), 38-44 (1997).
58. Mogensen J, Kubo T, Duque M et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J. Clin. Invest. 111(2), 209-216 (2003).
59. Angelini A, Calzolari V, Thiene G et al. Morphologic spectrum of primary restrictive cardiomyopathy. Am. J. Cardiol. 80(8), 1046-1050 (1997).
60. Feld S, Caspi A. Familial cardiomyopathy with variable hypertrophic and restrictive features and common HLA haplotype. Isr. J. Med. Sci. 28(5), 277-280 (1992).
61. Arbustini E, Morbini P, Grasso M et al. Restrictive cardiomyopathy, atrioventricular block and mild to subclinical myopathy in patients with desmin-immunoreactive material deposits. J. Am. Coll. Cardiol. 31(3), 645-653 (1998).
62. Bergman JE, Veenstra-Knol HE, Van Essen AJ et al. Two related Dutch families with a clinically variable presentation of cardioskeletal myopathy caused by a novel S13F mutation in the desmin gene. Eur. J. Med. Genet. 50(5), 355-366 (2007).
63. Kaminska A, Strelkov SV, Goudeau B et al. Small deletions disturb desmin architecture leading to breakdown of muscle cells and development of skeletal or cardioskeletal myopathy. Hum. Genet. 114(3), 306-313 (2004).
64. Li D, Tapscoft T, Gonzalez O et al. Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation 100(5), 461-464 (1999).
65. Silva CP, Bacal F, Benvenuti LA, Bocchi EA. Desmin-related restrictive cardiomyopathy. Arg. Bras. Cardiol. 89(6), 165-168 (2007).
66. Lubitz SA, Goldbarg SH, Mehta D. Sudden cardiac death in infiltrative cardiomyopathies: Sarcoidosis, scleroderma, amyloidosis, hemachromatosis. Prog. Cardiovasc. Dis. 51(1), 58-73 (2008).
67. Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N. Engl. J. Med. 336(4), 267-276 (1997).
68. Filopei J, Frishman W. Radiation-induced heart disease. Cardiol. Rev. 20(4), 184-188 (2012).
69. Bakalli A, Georgievska-Ismail L, Kocinaj D et al. Left ventricular and left atrial thrombi in sinus rhythm patients with dilated ischemic cardiomyopathy. Med. Arh. 66(3), 155-158 (2012).
70. Hirota Y, Kohriyama T, Hayashi T et al. Idiopathic restrictive cardiomyopathy: Differences of left ventricular relaxation and diastolic wave forms from constrictive pericarditis. Am. J. Cardiol. 52(3), 421-423 (1983).
71. Meaney E, Shabetai R, Bhargava V et al. Cardiac amyloidosis, contrictive pericarditis and restrictive cardiomyopathy. Am. J. Cardiol. 38(5), 547-556 (1976).
72. Kantor PF, Rusconi P, Lipshultz S, Mital S, Wilkinson JD, Burch M. Current applications and future needs for biomarkers in pediatric cardiomyopathy and heart failure: Summary from the second international conference on pediatric cardiomyopathy. Prog. Pediatr. Cardiol. 32(1), 11-14 (2011).
73. Leya FS, Arab D, Joyal D et al. The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J. Am. Coll. Cardiol. 45(11), 1900-1902 (2005).
74. Babuin L, Alegria JR, Oh JK, Nishimura RA, Jaffe AS. Brain natriuretic peptide levels in constrictive pericarditis and restrictive cardiomyopathy. J. Am. Coll. Cardiol. 47(7), 1489-1491 (2006).
75. Sengupta PP, Krishnamoorthy VK, Abhayaratna WP et al. Comparison of usefulness of tissue Doppler imaging versus brain natriuretic peptide for differentiation of constrictive pericardial disease from restrictive cardiomyopathy. Am. J. Cardiol. 102(3), 357-362 (2008).
76. Kaski JP, Syrris P, Burch M et al. Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. Heart 94(11), 1478-1484 (2008).
77. Rivenes SM, Kearney DL, Smith EO, Towbin JA, Denfield SW. Sudden death and cardiovascular collapse in children with restrictive cardiomyopathy. Circulation 102(8), 876-882 (2000).
78. Kubo T, Gimeno JR, Bahl A et al. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J. Am. Coll. Cardiol. 49(25), 2419-2426 (2007).
79. Ammash NM, Seward JB, Bailey KR, Edwards WD, Tajik AJ. Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation 101(21), 2490-2496 (2000).
80. Cetta F, O'Leary PW, Seward JB, Driscoll DJ. Idiopathic restrictive cardiomyopathy in childhood: Diagnostic features and clinical course. Mayo Clin. Proc. 70(7), 634-640 (1995).
81. Pignatelli RH, Mcmahon CJ, Dreyer WJ et al. Clinical characterization of left ventricular noncompaction in children: A relatively common form of cardiomyopathy. Circulation 108(21), 2672-2678 (2003).
82. Tsai SF, Ebenroth ES, Hurwitz RA, Cordes TM, Schamberger MS, Batra AS. Is left ventricular noncompaction in children truly an isolated lesion Pediatr. Cardiol. 30(5), 597-602 (2009).
83. Wald R, Veldtman G, Golding F, Kirsh J, McCrindle B, Benson L. Determinants of outcome in isolated ventricular noncompaction in childhood. Am. J. Cardiol. 94(12), 1581-1584 (2004).
84. Jenni R, Rojas J, Oechslin E. Isolated noncompaction of the myocardium. N. Engl. J. Med. 340(12), 966-967 (1999).
85. Ergul Y, Nisli K, Demirel A et al. Left ventricular non-compaction in children and adolescents: Clinical features, treatment and follow-up. Cardiol. J. 18(2), 176-184 (2011).
86. Dusek J, Ostadal B, Duskova M. Postnatal persistence of spongy myocardium with embryonic blood supply. Arch. Pathol. 99(6), 312-317 (1975).
87. Sedmera D, Pexieder T, Vuillemin M, Thompson RP, Anderson RH. Developmental patterning of the myocardium. Anat. Rec. 258(4), 319-337 (2000).
88. Towbin JA. Left ventricular noncompaction: A new form of heart failure. Heart Fail. Clin. 6(4), 453-469 (2010).
89. Martinez-Baca Lopez F, Alonso Bravo RM, Rodriguez Huerta DA. Echocardiographic features of non-compaction cardiomyopathy: Missed and misdiagnosed disease. Arq. Bras. Cardiol. 93(2), e33-e35 (2009).
90. Ozgur S, Senocak F, Orun UA et al. Ventricular non-compaction in children: Clinical characteristics and course. Interact. Cardiovasc. Thorac. Surg. 12(3), 370-373 (2011).
91. Murphy RT, Thaman R, Blanes JG et al. Natural history and familial characteristics of isolated left ventricular non-compaction. Eur. Heart J. 26(2), 187-192 (2005).
92. Chin TK, Perloff JK, Williams RG, Jue K, Mohrmann R. Isolated noncompaction of left ventricular myocardium. A study of eight cases. Circulation 82(2), 507-513 (1990).
93. Rosa LV, Salemi VM, Alexandre LM, Mady C. Noncompaction cardiomyopathy: A current view. Arq. Bras. Cardiol. 97(1), e13-e19 (2011).
94. Zuckerman WA, Richmond ME, Singh RK, Carroll SJ, Starc TJ, Addonizio LJ. Left-ventricular noncompaction in a pediatric population: Predictors of survival. Pediatr. Cardiol. 32(4), 406-412 (2011).
95. Richards A, Mao CY, Dobson NR. Left ventricular noncompaction: A rare cause of hydrops fetalis. Pediatr. Cardiol. 30(7), 985-988 (2009).
96. Ichida F, Tsubata S, Bowles KR et al. Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation 103(9), 1256-1263 (2001).
97. Sasse-Klaassen S, Probst S, Gerull B et al. Novel gene locus for autosomal dominant left ventricular noncompaction maps to chromosome 11p15. Circulation 109(22), 2720-2723 (2004).
98. Vatta M, Mohapatra B, Jimenez S et al. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J. Am. Coll. Cardiol. 42(11), 2014-2027 (2003).
99. Weiford BC, Subbarao VD, Mulhern KM. Noncompaction of the ventricular myocardium. Circulation 109(24), 2965-2971 (2004).
100. Jenni R, Oechslin EN, Van Der Loo B. Isolated ventricular non-compaction of the myocardium in adults. Heart 93(1), 11-15 (2007).
101. Oechslin EN, Attenhofer Jost CH, Rojas JR, Kaufmann PA, Jenni R. Long-term follow-up of 34 adults with isolated left ventricular noncompaction: A distinct cardiomyopathy with poor prognosis. J. Am. Coll. Cardiol. 36(2), 493-500 (2000).
102. Ichida F. Left ventricular noncompaction. Circ. J. 73(1), 19-26 (2009).
103. Yasukawa K, Terai M, Honda A, Kohno Y. Isolated noncompaction of ventricular myocardium associated with fatal ventricular fibrillation. Pediatr. Cardiol. 22(6), 512-514 (2001).
104. Ichida F, Hamamichi Y, Miyawaki T et al. Clinical features of isolated noncompaction of the ventricular myocardium: Long-term clinical course, hemodynamic properties, and genetic background. J. Am. Coll. Cardiol. 34(1), 233-240 (1999).
105. Hamamichi Y, Ichida F, Hashimoto I et al. Isolated noncompaction of the ventricular myocardium: Ultrafast computed tomography and magnetic resonance imaging. Int. J. Cardiovasc. Imaging 17(4), 305-314 (2001).
106. Saito K, Ibuki K, Yoshimura N et al. Successful cardiac resynchronization therapy in a 3-year-old girl with isolated left ventricular non-compaction and narrow QRS complex: A case report. Circ. J. 73(11), 2173-2177 (2009).
107. Lofiego C, Biagini E, Pasquale F et al. Wide spectrum of presentation and variable outcomes of isolated left ventricular non-compaction. Heart 93(1), 65-71 (2007).
108. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N. Engl. J. Med. 344(7), 501-509 (2001).
109. Cavallo A, Joseph CJ, Casta A. Cardiac complications in juvenile hyperthyroidism. Am. J. Dis. Child. 138(5), 479-482 (1984).
110. Cavallo A, Casta A, Fawcett HD, Nusynowitz ML, Wolf WJ. Is there a thyrotoxic cardiomyopathy in children J. Pediatr. 107(4), 531-536 (1985).
111. Gilbert-Barness E. Review: Metabolic cardiomyopathy and conduction system defects in children. Ann. Clin. Lab. Sci. 34(1), 15-34 (2004).
112. Jain V, Kannan L, Kumar P. Congenital hypopituitarism presenting as dilated cardiomyopathy in a child. J. Pediatr. Endocrinol. Metab. 24(9-10), 767-769 (2011).
113. Khochtali I, Hamza N, Harzallah O et al. Reversible dilated cardiomyopathy caused by hypothyroidism. Int. Arch. Med. 4, 20 (2011).
114. Micallef T, Gruppetta M, Cassar A, Fava S. Takotsubo cardiomyopathy and severe hypothyroidism. J. Cardiovasc. Med. (Hagerstown) 12(11), 824-827 (2011).
115. McElhinney DB, Colan SD, Moran AM et al. Recombinant human growth hormone treatment for dilated cardiomyopathy in children. Pediatrics 114(4), e452-e458 (2004).
116. Lipshultz SE, Vlach SA, Lipsitz SR, Sallan SE, Schwartz ML, Colan SD. Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics 115(6), 1613-1622 (2005).
117. Ibe W, Saraste A, Lindemann S et al. Cardiomyocyte apoptosis is related to left ventricular dysfunction and remodelling in dilated cardiomyopathy, but is not affected by growth hormone treatment. Eur. J. Heart Fail. 9(2), 160-167 (2007).
118. Kobayashi D, Cook AL, Williams DA. Progressively worsening hypertrophic cardiomyopathy in a child with newly diagnosed Costello syndrome while receiving growth hormone therapy. Cardiol. Young 20(4), 459-461 (2010).
119. Falcao-Pires I, Leite-Moreira AF. Diabetic cardiomyopathy: Understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail. Rev. 17(3), 325-344 (2012).
120. Maisch B, Alter P, Pankuweit S. Diabetic cardiomyopathy - fact or fiction Herz 36(2), 102-115 (2011).
121. Tarquini R, Lazzeri C, Pala L, Rotella CM, Gensini GF. The diabetic cardiomyopathy. Acta Diabetol. 48(3), 173-181 (2011).
122. Von Bibra H, St John Sutton M. Diastolic dysfunction in diabetes and the metabolic syndrome: Promising potential for diagnosis and prognosis. Diabetologia 53(6), 1033-1045 (2010).
123. Grandi AM, Piantanida E, Franzetti I et al. Effect of glycemic control on left ventricular diastolic function in Type 1 diabetes mellitus. Am. J. Cardiol. 97(1), 71-76 (2006).
124. Suys BE, Katier N, Rooman RP et al. Female children and adolescents with Type 1 diabetes have more pronounced early echocardiographic signs of diabetic cardiomyopathy. Diabetes Care 27(8), 1947-1953 (2004).
125. Salem M, El Behery S, Adly A, Khalil D, El Hadidi E. Early predictors of myocardial disease in children and adolescents with Type 1 diabetes mellitus. Pediatr. Diabetes 10(8), 513-521 (2009).
126. Wong C, Marwick TH. Obesity cardiomyopathy: Pathogenesis and pathophysiology. Nat. Clin. Pract. Cardiovasc. Med. 4(8), 436-443 (2007).
127. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation 67(5), 968-977 (1983).
128. Mehta SK, Holliday C, Hayduk L, Wiersma L, Richards N, Younoszai A. Comparison of myocardial function in children with body mass indexes /=25 versus those
129. Obert P, Gueugnon C, Nottin S et al. Two-dimensional strain and twist by vector velocity imaging in adolescents with severe obesity. Obesity (Silver Spring) 20(12), 2397-2405 (2012).
130. Unger RH. Lipotoxic disease. Annu. Rev. Med. 53, 319-336 (2002).
131. Qureshi MY, Wilkinson JD, Lipshultz SE. The relationship of childhood obesity with cardiomyopathy and heart failure. In: Pediatric Metabolic Syndrome Comprehensive Clinical Review and Related Health Issues, Lipshultz SE, Messiah SE, Miller TL (Eds). Springer-Verlag, London, UK, 199-215 (2012).
132. Schrier RW. Cardiorenal versus renocardiac syndrome: Is there a difference Nat. Clin. Pract. Nephrol. 3(12), 637 (2007).
133. Anavekar NS, Mcmurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N. Engl. J. Med. 351(13), 1285-1295 (2004).
134. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 32(5 Suppl. 3), S112-S119 (1998).
135. Parekh RS, Carroll CE, Wolfe RA, Port FK. Cardiovascular mortality in children and young adults with end-stage kidney disease. J. Pediatr. 141(2), 191-197 (2002).
136. Shroff R, Weaver DJ Jr, Mitsnefes MM. Cardiovascular complications in children with chronic kidney disease. Nat. Rev. Nephrol. 7(11), 642-649 (2011).
137. Mitsnefes MM, Barletta GM, Dresner IG et al. Severe cardiac hypertrophy and long-term dialysis: The Midwest Pediatric Nephrology Consortium study. Pediatr. Nephrol. 21(8), 1167-1170 (2006).
138. Gruppen MP, Groothoff JW, Prins M et al. Cardiac disease in young adult patients with end-stage renal disease since childhood: A Dutch cohort study. Kidney Int. 63(3), 1058-1065 (2003).
139. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 36(2), 286-290 (1989).
140. Chavers BM, Li S, Collins AJ, Herzog CA. Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int. 62(2), 648-653 (2002).
141. Maron BJ. Sudden death in young athletes. N. Engl. J. Med. 349(11), 1064-1075 (2003).
142. Amann K, Tyralla K, Gross ML et al. Cardiomyocyte loss in experimental renal failure: Prevention by ramipril. Kidney Int. 63(5), 1708-1713 (2003).
143. Tyralla K, Adamczak M, Benz K et al. High-dose enalapril treatment reverses myocardial fibrosis in experimental uremic cardiomyopathy. PLoS ONE 6(1), e15287 (2011).
144. Ritz E. Left ventricular hypertrophy in renal disease: Beyond preload and afterload. Kidney Int. 75(8), 771-773 (2009).
145. Pilz S, Tomaschitz A, Marz W et al. Vitamin D, cardiovascular disease and mortality. Clin. Endocrinol. (Oxf.) 75(5), 575-584 (2011).
146. Hsu HJ, Wu MS. Fibroblast growth factor 23: A possible cause of left ventricular hypertrophy in hemodialysis patients. Am. J. Med. Sci. 337(2), 116-122 (2009).
147. Gutierrez OM, Januzzi JL, Isakova T et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119(19), 2545-2552 (2009).
148. Holick MF. Vitamin D deficiency. N. Engl. J. Med. 357(3), 266-281 (2007).
149. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am. J. Physiol. Renal Physiol. 289(1), F8-F28 (2005).
150. Tishkoff DX, Nibbelink KA, Holmberg KH, Dandu L, Simpson RU. Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology 149(2), 558-564 (2008).
151. Seeherunvong W, Abitbol CL, Chandar J, Zilleruelo G, Freundlich M. Vitamin D insufficiency and deficiency in children with early chronic kidney disease. J. Pediatr. 154(6), 906-911 e901 (2009).
152. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 72(8), 1004-1013 (2007).
153. Maiya S, Sullivan I, Allgrove J et al. Hypocalcaemia and vitamin D deficiency: An important, but preventable, cause of life-threatening infant heart failure. Heart 94(5), 581-584 (2008).
154. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch. Intern. Med. 168(15), 1629-1637 (2008).
155. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S. Vitamin D status and mortality risk in CKD: A meta-analysis of prospective studies. Am. J. Kidney Dis. 58(3), 374-382 (2011).
156. Sun Q, Shi L, Rimm EB et al. Vitamin D intake and risk of cardiovascular disease in US men and women. Am. J. Clin. Nutr. 94(2), 534-542 (2011).
157. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann. Intern. Med. 152(5), 315-323 (2010).
158. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 71(1), 31-38 (2007).
159. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med. 349(5), 446-456 (2003).
160. Kovesdy CP. Survival benefits with vitamin D receptor activation: New insights since 2003. Clin. J. Am. Soc. Nephrol. 5(9), 1704-1709 (2010).
161. Kim HW, Park CW, Shin YS et al. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin. Pract. 102(1), c21-c29 (2006).
162. Mizobuchi M, Nakamura H, Tokumoto M et al. Myocardial effects of VDR activators in renal failure. J. Steroid Biochem. Mol. Biol. 121(1-2), 188-192 (2010).
163. Thadhani R, Appelbaum E, Pritchett Y et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial. JAMA 307(7), 674-684 (2012).
164. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 110(2), 229-238 (2002).
165. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: A negative endocrine regulator of the renin-angiotensin system and blood pressure. J. Steroid Biochem. Mol. Biol. 89-90(1-5), 387-392 (2004).
166. Xiang W, Kong J, Chen S et al. Cardiac hypertrophy in vitamin D receptor knockout mice: Role of the systemic and cardiac renin-angiotensin systems. Am. J. Physiol. Endocrinol. Metab. 288(1), e125-e132 (2005).
167. Bodyak N, Ayus JC, Achinger S et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc. Natl Acad. Sci. USA 104(43), 16810-16815 (2007).
168. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 74(2), 170-179 (2008).
169. Yuan W, Pan W, Kong J et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J. Biol. Chem. 282(41), 29821-29830 (2007).
170. Fryer RM, Rakestraw PA, Nakane M et al. Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephron Physiol. 106(4), 76-81 (2007).
171. Li YC. Vitamin D: Roles in renal and cardiovascular protection. Curr. Opin. Nephrol. Hypertens. 21(1), 72-79 (2012).
172. Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II. Role of an intracardiac renin-angiotensin system. Annu. Rev. Physiol. 54, 227-241 (1992).
173. Freundlich M, Quiroz Y, Zhang Z et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 74(11), 1394-1402 (2008).
174. Wollert KC, Drexler H. The renin- angiotensin system and experimental heart failure. Cardiovasc. Res. 43(4), 838-849 (1999).
175. Hasegawa H, Nagano N, Urakawa I et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 78(10), 975-980 (2010).
176. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 359(6), 584-592 (2008).
177. Wesseling-Perry K, Pereira RC, Wang H et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J. Clin. Endocrinol. Metab. 94(2), 511-517 (2009).
178. Isakova T, Xie H, Yang W et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305(23), 2432-2439 (2011).
179. Seeherunvong W, Abitbol CL, Chandar J, Rusconi P, Zilleruelo GE, Freundlich M. Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis. Pediatr. Nephrol. 27(11), 2129-2136 (2012).
180. Isakova T, Houston J, Santacruz L et al. Associations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure. Pediatr. Nephrol. doi:10.1007/ s00467-013-2515-7 (2013) (Epub ahead of print).
181. Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury P, Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: Prevalence and predictors. Pediatr. Nephrol. 14(10-11), 898-902 (2000).
182. Borzych D, Bakkaloglu SA, Zaritsky J et al. Defining left ventricular hypertrophy in children on peritoneal dialysis. Clin. J. Am. Soc. Nephrol. 6(8), 1934-1943 (2011).
183. Daniels SR, Kimball TR, Morrison JA, Khoury P, Meyer RA. Indexing left ventricular mass to account for differences in body size in children and adolescents without cardiovascular disease. Am. J. Cardiol. 76(10), 699-701 (1995).
184. Khoury PR, Mitsnefes M, Daniels SR, Kimball TR. Age-specific reference intervals for indexed left ventricular mass in children. J. Am. Soc. Echocardiogr. 22(6), 709-714 (2009).
185. Bakkaloglu SA, Borzych D, Soo Ha I et al. Cardiac geometry in children receiving chronic peritoneal dialysis: Findings from the International Pediatric Peritoneal Dialysis Network (IPPN) registry. Clin. J. Am. Soc. Nephrol. 6(8), 1926-1933 (2011).
186. Hughes SE. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J. Histochem. Cytochem. 45(7), 1005-1019 (1997).
187. Liu L, Pasumarthi KB, Padua RR et al. Adult cardiomyocytes express functional high-affinity receptors for basic fibroblast growth factor. Am. J. Physiol. 268(5 Pt 2), H1927-H1938 (1995).
188. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121(11), 4393-4408 (2011).
189. Freundlich M, Li YC, Weisinger JR, Quiroz Y, Bravo J, Rodriguez-Iturbe B. Paricalcitol downregulates myocardial renin- angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats. Am. J. Hypertens. doi:10.1093/ ajh/hpt177 (2013) (Epub ahead of print).
190. Srivaths PR, Goldstein SL, Silverstein DM, Krishnamurthy R, Brewer ED. Elevated FGF-23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr. Nephrol. 26(6), 945-951 (2011).
191. Desjardins L, Liabeuf S, Renard C et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos. Int. 23(7), 2017-2025 (2012).
192. Razzaque MS. The FGF23-Klotho axis: Endocrine regulation of phosphate homeostasis. Nat. Rev. Endocrinol. 5(11), 611-619 (2009).
193. Chen S, Gardner DG. Liganded vitamin D receptor displays anti-hypertrophic activity in the murine heart. J. Steroid Biochem. Mol. Biol. 136, 150-155 (2012).
194. Davos CH, Doehner W, Rauchhaus M et al. Body mass and survival in patients with chronic heart failure without cachexia: The importance of obesity. J. Card. Fail. 9(1), 29-35 (2003).
195. Trumbo P, Schlicker S, Yates AA, Poos M. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J. Am. Diet. Assoc. 102(11), 1621-1630 (2002).
196. Monsen ER. Dietary reference intakes for the antioxidant nutrients: Vitamin C, vitamin E, selenium, and carotenoids. J. Am. Diet. Assoc. 100(6), 637-640 (2000).
197. Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its panel on folate, other B vitamins, and chlorine. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. In: The National Academies Collection: Reports Funded by National Institutes of Health. National Academies Press, DC, USA (1998).
198. Electrolytes P.o.D.R.I.f., Water, and S.C.o.t.S.E.o.D.R. Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. The National Academies Press, Washington, DC, USA (2005).
199. Trumbo P, Yates AA, Schlicker S, Poos M. Dietary reference intakes: Vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. J. Am. Diet. Assoc. 101(3), 294-301 (2001).
200. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes; Food and Nutrition Board; Institute of Medicine. In: DRI Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. National Academy Press, DC, USA (1997).
201. Broqvist M, Arnqvist H, Dahlstrom U, Larsson J, Nylander E, Permert J. Nutritional assessment and muscle energy metabolism in severe chronic congestive heart failure - effects of long-term dietary supplementation. Eur. Heart J. 15(12), 1641-1650 (1994).
202. Sole MJ, Jeejeebhoy KN. Conditioned nutritional requirements: Therapeutic relevance to heart failure. Herz 27(2), 174-178 (2002).
203. Miller TL, Neri D, Extein J, Somarriba G, Strickman-Stein N. Nutrition in pediatric cardiomyopathy. Prog. Pediatr. Cardiol. 24(1), 59-71 (2007).
204. Szasz T, Thakali K, Fink GD, Watts SW. A comparison of arteries and veins in oxidative stress: Producers, destroyers, function, and disease. Exp. Biol. Med. (Maywood) 232(1), 27-37 (2007).
205. Riccioni G, D'orazio N, Franceschelli S, Speranza L. Marine carotenoids and cardiovascular risk markers. Mar. Drugs 9(7), 1166-1175 (2011).
206. Voutilainen S, Nurmi T, Mursu J, Rissanen TH. Carotenoids and cardiovascular health. Am. J. Clin. Nutr. 83(6), 1265-1271 (2006).
207. Miwa K, Kishimoto C, Nakamura H et al. Serum thioredoxin and alpha-tocopherol concentrations in patients with major risk factors. Circ. J. 69(3), 291-294 (2005).
208. Turan B, Vassort G. Vitamin E in oxidant stress-related cardiovascular pathologies: Focus on experimental studies. Curr. Pharm. Des. 17(21), 2155-2169 (2011).
209. Saremi A, Arora R. Vitamin E and cardiovascular disease. Am. J. Ther. 17(3), e56-e65 (2010).
210. Little PJ, Bhattacharya R, Moreyra AE, Korichneva IL. Zinc and cardiovascular disease. Nutrition 26(11-12), 1050-1057 (2010).
211. Strassburger M, Bloch W, Sulyok S et al. Heterozygous deficiency of manganese superoxide dismutase results in severe lipid peroxidation and spontaneous apoptosis in murine myocardium in vivo. Free Radic. Biol. Med. 38(11), 1458-1470 (2005).
212. Inge TH, Krebs NF, Garcia VF et al. Bariatric surgery for severely overweight adolescents: Concerns and recommendations. Pediatrics 114(1), 217-223 (2004).
213. Frustaci A, Sabbioni E, Fortaner S et al. Selenium- and zinc-deficient cardiomyopathy in human intestinal malabsorption: Preliminary results of selenium/zinc infusion. Eur. J. Heart Fail. 14(2), 202-210 (2012).
214. Kosar F, Sahin I, Taskapan C et al. Trace element status (Se, Zn, Cu) in heart failure. Anadolu. Kardiyol. Derg. 6(3), 216-220 (2006).
215. Sirikonda NS, Patten WD, Phillips JR, Mullett CJ. Ketogenic diet: Rapid onset of selenium deficiency-induced cardiac decompensation. Pediatr. Cardiol. 33(5), 834-838 (2012).
216. Azuma J, Sawamura A, Awata N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ. J. 56(1), 95-99 (1992).
217. Schaffer SW, Jong CJ, Ramila KC, Azuma J. Physiological roles of taurine in heart and muscle. J. Biomed Sci. 17 (Suppl. 1), S2 (2010).
218. Ito T, Kimura Y, Uozumi Y et al. Taurine depletion caused by knocking out the taurine transporter gene leads to cardiomyopathy with cardiac atrophy. J. Mol. Cell. Cardiol. 44(5), 927-937 (2008).
219. Gesuete V, Ragni L, Picchio FM. The big heart' of carnitine. G. Ital. Cardiol. (Rome) 11(9), 703-705 (2010).
220. Magoulas PL, El-Hattab AW. Systemic primary carnitine deficiency: An overview of clinical manifestations, diagnosis, and management. Orphanet. J. Rare Dis. 7(1), 68 (2012).
221. Baragou S, Pio M, Di Bernardo S et al. A cause of dilated cardiomyopathy in child: Primary carnitine deficiency. Ann. Cardiol. Angeiol. (Paris) doi:10.1016/j. ancard.2011.12.006 (2011) (Epub ahead of print).
222. Benzarouel D, Hasni K, Ashab H, El Hattaoui M. [A reversible cause of cardiomyopathy: Hypocalcemia]. Ann. Cardiol. Angeiol. (Paris) doi:10.1016/j. ancard.2012.04.003 (2012) (Epub ahead of print).
223. Vacek JL, Vanga SR, Good M, Lai SM, Lakkireddy D, Howard PA. Vitamin D deficiency and Supplementation and relation to cardiovascular health. Am. J. Cardiol. 109(3), 359-363 (2012).
224. Verma S, Khadwal A, Chopra K, Rohit M, Singhi S. Hypocalcemia nutritional rickets: A curable cause of dilated cardiomyopathy. J. Trop. Pediatr. 57(2), 126-128 (2011).
225. Cotran RM, Kumar V, Robbins SL. Robbin's Pathologic Basis of Disease, 5th Edition. Michael B, Cohen MD (Eds). Elsevier, PA, USA (1994).